Global Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity
Global pharmaceutical manufacturing industry market will reach $25.77 billion by 2032, growing by 9.3% annually over 2022-2032. The growth is driven by the increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high R&D investment in pharmaceutical industry, increasing per capita healthcare expenditure, and technological advancements in manufacturing processes.
Highlighted with 142 tables and 105 figures, this 228-page report “Global Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmaceutical manufacturing industry market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global pharmaceutical manufacturing industry market in every aspect of the classification from perspectives of Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region.
Based on Formulation, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration
By Consumer Group, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Children & Adolescents (17 years old and below)
• Adults (18-64 years old)
• Geriatric (65 years old and above)
By Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications
By Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
By Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Retail Channels
• Non-retail Channels
By Manufacturing Facility, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• In-house Facility
• Outsourced Facility
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by Formulation, Route of Administration, and Drug Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Aenova Group
Amgen Inc.
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin Limited
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Patheon Inc.
Pfizer CentreSource
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 13
1.1 Industry Definition and Research Scope 13
1.1.1 Industry Definition 13
1.1.2 Research Scope 14
1.2 Research Methodology 17
1.2.1 Overview of Market Research Methodology 17
1.2.2 Market Assumption 18
1.2.3 Secondary Data 18
1.2.4 Primary Data 18
1.2.5 Data Filtration and Model Design 19
1.2.6 Market Size/Share Estimation 20
1.2.7 Research Limitations 21
1.3 Executive Summary 22
2 Market Overview and Dynamics 25
2.1 Market Size and Forecast 25
2.1.1 Impact of COVID-19 on World Economy 28
2.1.2 Impact of COVID-19 on the Market 31
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 33
2.2 Major Growth Drivers 37
2.3 Market Restraints and Challenges 44
2.4 Emerging Opportunities and Market Trends 47
2.5 Porter’s Fiver Forces Analysis 51
3 Segmentation of Global Market by Formulation 55
3.1 Market Overview by Formulation 55
3.2 Tablets 57
3.3 Capsules 58
3.4 Injectable 59
3.5 Sprays 60
3.6 Suspensions 61
3.7 Powders 62
3.8 Other Formulations 63
4 Segmentation of Global Market by Route of Administration 64
4.1 Market Overview by Route of Administration 64
4.2 Oral Medicine 66
4.3 Topical Medicine 67
4.4 Parenteral Medicine 68
4.5 Inhalations 69
4.6 Other Routes of Administration 70
5 Segmentation of Global Market by Consumer Group 71
5.1 Market Overview by Consumer Group 71
5.2 Children & Adolescents (17 years old and below) 73
5.3 Adults (18-64 years old) 74
5.4 Geriatric (65 years old and above) 75
6 Segmentation of Global Market by Therapeutic Application 76
6.1 Market Overview by Therapeutic Application 76
6.2 Cardiovascular Diseases 78
6.3 Pain 79
6.4 Diabetes 80
6.5 Cancer 81
6.6 Respiratory Diseases 82
6.7 Neurological Diseases 83
6.8 Orthopedics 84
6.9 Other Applications 85
7 Segmentation of Global Market by Drug Type 86
7.1 Market Overview by Drug Type 86
7.2 Branded Prescription Drugs 88
7.3 Generic Prescription Drugs 89
7.4 OTC Drugs 90
8 Segmentation of Global Market by Distribution Channel 91
8.1 Market Overview by Distribution Channel 91
8.2 Retail Channels 93
8.3 Non-retail Channels 94
9 Segmentation of Global Market by Manufacturing Facility 95
9.1 Market Overview by Manufacturing Facility 95
9.2 In-house Facility 97
9.3 Outsourced Facility 98
10 Segmentation of Global Market by Region 99
10.1 Geographic Market Overview 2022-2032 99
10.2 North America Market 2022-2032 by Country 103
10.2.1 Overview of North America Market 103
10.2.2 U.S. 107
10.2.3 Canada 114
10.2.4 Mexico 116
10.3 European Market 2022-2032 by Country 118
10.3.1 Overview of European Market 118
10.3.2 Germany 122
10.3.3 U.K. 124
10.3.4 France 126
10.3.5 Spain 128
10.3.6 Italy 130
10.3.7 Netherlands 132
10.3.8 Rest of European Market 134
10.4 Asia-Pacific Market 2022-2032 by Country 136
10.4.1 Overview of Asia-Pacific Market 136
10.4.2 Japan 140
10.4.3 China 143
10.4.4 Australia 145
10.4.5 India 147
10.4.6 South Korea 149
10.4.7 Rest of APAC Region 151
10.5 South America Market 2022-2032 by Country 153
10.5.1 Argentina 156
10.5.2 Brazil 158
10.5.3 Chile 160
10.5.4 Rest of South America Market 162
10.6 MEA Market 2022-2032 by Country 163
10.6.1 UAE 166
10.6.2 Saudi Arabia 168
10.6.3 South Africa 170
10.6.4 Other National Markets 172
11 Competitive Landscape 173
11.1 Overview of Key Vendors 173
11.2 New Product Launch, Partnership, Investment, and M&A 176
11.3 Company Profiles 177
Abbott Laboratories 177
Aenova Group 179
Amgen Inc. 183
AstraZeneca 186
Catalent Inc. 189
Eli Lilly and Company 192
F. Hoffmann-La Roche Ltd. 194
Gilead Sciences Inc. 196
GlaxoSmithKline plc 198
Johnson & Johnson 202
Lonza Group 204
Lupin Limited 207
Merck & Co., Inc. 209
Novartis AG 211
Novo Nordisk 213
Patheon Inc. 216
Pfizer CentreSource 220
Sanofi SA 224
Takeda 226
RELATED REPORTS 228
List of Tables:
Table 1. Snapshot of Global Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032 23
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change 27
Table 3. World Economic Outlook, 2021-2031 29
Table 4. World Economic Outlook, 2021-2023 30
Table 5. Scenarios for Economic Impact of Ukraine Crisis 34
Table 6. World Health Spending by Region, $ bn, 2013-2020 43
Table 7. Main Product Trends and Market Opportunities in Global Pharmaceutical Manufacturing Industry 47
Table 8. Global Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 55
Table 9. Global Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 64
Table 10. Global Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn 71
Table 11. Global Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn 76
Table 12. Global Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 86
Table 13. Global Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn 91
Table 14. Global Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn 95
Table 15. Global Pharmaceutical Manufacturing Industry by Region, 2022-2032, $ mn 100
Table 16. Leading National Pharmaceutical Manufacturing Industry, 2022 and 2032, $ mn 102
Table 17. North America Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 105
Table 18. U.S. Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 109
Table 19. U.S. Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 109
Table 20. U.S. Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 109
Table 21. Canada Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 115
Table 22. Canada Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 115
Table 23. Canada Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 115
Table 24. Mexico Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 117
Table 25. Mexico Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 117
Table 26. Mexico Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 117
Table 27. Europe Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 121
Table 28. Germany Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 123
Table 29. Germany Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 123
Table 30. Germany Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 123
Table 31. U.K. Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 125
Table 32. U.K. Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 125
Table 33. U.K. Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 125
Table 34. France Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 127
Table 35. France Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 127
Table 36. France Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 127
Table 37. Spain Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 129
Table 38. Spain Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 129
Table 39. Spain Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 129
Table 40. Italy Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 131
Table 41. Italy Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 131
Table 42. Italy Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 131
Table 43. Netherlands Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 133
Table 44. Netherlands Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 133
Table 45. Netherlands Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 133
Table 46. Pharmaceutical Manufacturing Industry in Rest of Europe by Country, 2022-2032, $ mn 135
Table 47. APAC Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 138
Table 48. Japan Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 142
Table 49. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 142
Table 50. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 142
Table 51. China Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 144
Table 52. China Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 144
Table 53. China Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 144
Table 54. Australia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 146
Table 55. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 146
Table 56. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 146
Table 57. India Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 148
Table 58. India Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 148
Table 59. India Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 148
Table 60. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 150
Table 61. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 150
Table 62. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 150
Table 63. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2022-2032, $ mn 152
Table 64. South America Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 155
Table 65. Argentina Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 157
Table 66. Argentina Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 157
Table 67. Argentina Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 157
Table 68. Brazil Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 159
Table 69. Brazil Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 159
Table 70. Brazil Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 159
Table 71. Chile Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 161
Table 72. Chile Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 161
Table 73. Chile Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 161
Table 74. MEA Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 165
Table 75. UAE Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 167
Table 76. UAE Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 167
Table 77. UAE Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 167
Table 78. Saudi Arabia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 169
Table 79. Saudi Arabia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 169
Table 80. Saudi Arabia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 169
Table 81. South Africa Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 171
Table 82. South Africa Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 171
Table 83. South Africa Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 171
Table 84. Abbott Laboratories: Company Snapshot 177
Table 85. Abbott Laboratories: Business Segmentation 178
Table 86. Abbott Laboratories: Product Portfolio 178
Table 87. Aenova Group: Company Snapshot 179
Table 88. Aenova Group: Business Segmentation 180
Table 89. Aenova Group: Revenue by Product, 2018-2019, thousand Euro 181
Table 90. Aenova Group: Recent Developments 182
Table 91. Amgen Inc.: Company Snapshot 183
Table 92. Amgen Inc.: Approved Drugs or Therapeutic Biologicals 184
Table 93. Astrazeneca: Company Snapshot 186
Table 94. Catalent Inc.: Company Snapshot 189
Table 95. Catalent Inc.: Business Segmentation in 2018 190
Table 96. Catalent Inc.: Product Portfolio 190
Table 97. Catalent Inc.: Revenue, 2018-2020, $ million 191
Table 98. Catalent Inc.: Revenue by Region in 2018 191
Table 99. Eli Lilly and Company: Company Snapshot 192
Table 100. Eli Lilly and Company: Pharmaceutical Brands 193
Table 101. F. Hoffmann-La Roche: Company Snapshot 194
Table 102. F. Hoffmann-La Roche: Business Segmentation 194
Table 103. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 195
Table 104. Gilead Sciences: Company Snapshot 196
Table 105. Gilead Sciences: Main Products 196
Table 106. GlaxoSmithKline: Company Snapshot 198
Table 107. GlaxoSmithKline: Business Segmentation 199
Table 108. GlaxoSmithKline: Product Portfolio 200
Table 109. GlaxoSmithKline: Revenue, 2018-2020, $ bn 201
Table 110. Johnson & Johnson: Company Snapshot 202
Table 111. Johnson & Johnson: Business Segments 202
Table 112. Lonza Group: Company Snapshot 204
Table 113. Lonza Group: Business Segmentation in 2018 204
Table 114. Lonza Group: Product Portfolio 205
Table 115. Lonza Group: Revenue by Region in 2018 205
Table 116. Lupin Limited: Company Snapshot 207
Table 117. Lupin Limited: Business Segmentation 208
Table 118. Merck & Co., Inc.: Company Snapshot 209
Table 119. Merck & Co., Inc.: Business Segmentation 209
Table 120. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 210
Table 121. Novartis International AG: Company Snapshot 211
Table 122. Novartis International AG: Business Segmentation 211
Table 123. Novartis International AG: Revenue, 2017-2019, $ bn 212
Table 124. Novo Nordisk: Company Snapshot 213
Table 125. Novo Nordisk: Product Portfolio 214
Table 126. Patheon Inc.: Company Snapshot 216
Table 127. Patheon Inc.: Business Segmentation in 2018 217
Table 128. Patheon Inc.: Product Portfolio 217
Table 129. Patheon Inc.: Revenue, 2017-2019, $ billion 218
Table 130. Patheon Inc.: Revenue by Region in 2018 218
Table 131. Patheon Inc.: Recent Developments 219
Table 132. Pfizer CentreSource: Company Snapshot 220
Table 133. Pfizer CentreSource: Business Segmentation in 2018 221
Table 134. Pfizer CentreSource: Product Portfolio 221
Table 135. Pfizer CentreSource: Revenue, 2017-2019, $ billion 222
Table 136. Pfizer CentreSource: Revenue by Region in 2018 222
Table 137. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot 222
Table 138. Pfizer CentreSource: Recent Developments 223
Table 139. Sanofi: Company Snapshot 224
Table 140. Sanofi: Business Segmentation 224
Table 141. Sanofi: Revenue, 2018-2020, $ bn 225
Table 142. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 226List of Figures:
Figure 1. Research Method Flow Chart 17
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 20
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 22
Figure 4. Global Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 25
Figure 5. World Healthcare Services Production, annual percentage change 27
Figure 6. Impact of COVID-19 on Business 31
Figure 7. Primary Drivers and Impact Factors of Global Pharmaceutical Manufacturing Industry 37
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century 40
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million 41
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 42
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 42
Figure 12. Primary Restraints and Impact Factors of Global Pharmaceutical Manufacturing Industry 44
Figure 13. Investment Opportunity Analysis 48
Figure 14. Porter’s Fiver Forces Analysis of Global Pharmaceutical Manufacturing Industry 51
Figure 15. Breakdown of Global Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue 56
Figure 16. Global Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%) 56
Figure 17. Global Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn 57
Figure 18. Global Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn 58
Figure 19. Global Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn 59
Figure 20. Global Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn 60
Figure 21. Global Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn 61
Figure 22. Global Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn 62
Figure 23. Global Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn 63
Figure 24. Breakdown of Global Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue 65
Figure 25. Global Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 65
Figure 26. Global Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn 66
Figure 27. Global Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn 67
Figure 28. Global Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn 68
Figure 29. Global Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn 69
Figure 30. Global Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn 70
Figure 31. Breakdown of Global Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue 72
Figure 32. Global Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%) 72
Figure 33. Global Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn 73
Figure 34. Global Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn 74
Figure 35. Global Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn 75
Figure 36. Breakdown of Global Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue 77
Figure 37. Global Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%) 77
Figure 38. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn 78
Figure 39. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn 79
Figure 40. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn 80
Figure 41. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn 81
Figure 42. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn 82
Figure 43. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn 83
Figure 44. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn 84
Figure 45. Global Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn 85
Figure 46. Breakdown of Global Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue 87
Figure 47. Global Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 87
Figure 48. Global Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn 88
Figure 49. Global Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn 89
Figure 50. Global Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn 90
Figure 51. Breakdown of Global Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue 91
Figure 52. Global Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 92
Figure 53. Global Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn 93
Figure 54. Global Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn 94
Figure 55. Breakdown of Global Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue 95
Figure 56. Global Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%) 96
Figure 57. Global Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn 97
Figure 58. Global Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn 98
Figure 59. Global Market Snapshot by Region 99
Figure 60. Geographic Spread of Worldwide Pharmaceutical Manufacturing Industry, 2022-2032, % of Sales Revenue 100
Figure 61. Global Addressable Market Cap in 2023-2032 by Region, Value ($ mn) and Share (%) 101
Figure 62. North American Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 104
Figure 63. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 105
Figure 64. Contribution to North America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 106
Figure 65. U.S. Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 108
Figure 66. Sources of API Manufacturing by Product Area in U.S., as of May 2021 110
Figure 67. Manufacturing Locations of Essential Medicines in U.S., as of May 2021 111
Figure 68. Count of High-Capacity API Sites in U.S. in 2021 112
Figure 69. FDA-Approved API Manufacturing Sites in U.S., 2016-2021 113
Figure 70. Canada Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 114
Figure 71. Pharmaceutical Manufacturing Industry in Mexico, 2022-2032, $ mn 116
Figure 72. European Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 119
Figure 73. Breakdown of European Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 120
Figure 74. Contribution to Europe 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 121
Figure 75. Pharmaceutical Manufacturing Industry in Germany, 2022-2032, $ mn 122
Figure 76. Pharmaceutical Manufacturing Industry in U.K., 2022-2032, $ mn 124
Figure 77. Pharmaceutical Manufacturing Industry in France, 2022-2032, $ mn 126
Figure 78. Pharmaceutical Manufacturing Industry in Spain, 2022-2032, $ mn 128
Figure 79. Pharmaceutical Manufacturing Industry in Italy, 2022-2032, $ mn 130
Figure 80. Pharmaceutical Manufacturing Industry in Netherlands, 2022-2032, $ mn 132
Figure 81. Pharmaceutical Manufacturing Industry in Rest of Europe, 2022-2032, $ mn 134
Figure 82. Asia-Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 137
Figure 83. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 137
Figure 84. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 85. Pharmaceutical Manufacturing Industry in Japan, 2022-2032, $ mn 141
Figure 86. Pharmaceutical Manufacturing Industry in China, 2022-2032, $ mn 143
Figure 87. Pharmaceutical Manufacturing Industry in Australia, 2022-2032, $ mn 145
Figure 88. Pharmaceutical Manufacturing Industry in India, 2022-2032, $ mn 147
Figure 89. Pharmaceutical Manufacturing Industry in South Korea, 2022-2032, $ mn 149
Figure 90. Pharmaceutical Manufacturing Industry in Rest of APAC, 2022-2032, $ mn 151
Figure 91. South America Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 154
Figure 92. Breakdown of South America Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 154
Figure 93. Contribution to South America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 155
Figure 94. Pharmaceutical Manufacturing Industry in Argentina, 2022-2032, $ mn 156
Figure 95. Pharmaceutical Manufacturing Industry in Brazil, 2022-2032, $ mn 158
Figure 96. Pharmaceutical Manufacturing Industry in Chile, 2022-2032, $ mn 160
Figure 97. Pharmaceutical Manufacturing Industry in Rest of South America, 2022-2032, $ mn 162
Figure 98. Pharmaceutical Manufacturing Industry in Middle East and Africa (MEA), 2022-2032, $ mn 164
Figure 99. Breakdown of MEA Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 164
Figure 100. Contribution to MEA 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 165
Figure 101. Pharmaceutical Manufacturing Industry in UAE, 2022-2032, $ mn 166
Figure 102. Pharmaceutical Manufacturing Industry in Saudi Arabia, 2022-2032, $ mn 168
Figure 103. Pharmaceutical Manufacturing Industry in South Africa, 2022-2032, $ mn 170
Figure 104. Growth Stage of Global 3D Printing Industry over the Forecast Period 173
Figure 105. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 187
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|